The move extends strategic momentum from a September 9, 2026 restructuring in which PRF Technologies (Nasdaq: PRFX) established GridFeed as a dedicated corporate unit focused on forming alliances with data center operators. The initiative seeks to give operators enhanced capacity management tools, reduced electricity …
The update follows earlier positive initial efficacy data from Part C of the Phase 2 expansion trial, which evaluated ateganosine followed by cemiplimab in third-line advanced NSCLC. That cohort showed an interim disease control rate of 90.5%, data that had been noted on July …
The new collaboration sits alongside Tiziana Life Sciences' (Nasdaq: TLSA) ongoing, blinded Phase 2 trial in non-active secondary progressive multiple sclerosis, for which a data readout remains on track for October 2026. Together, the two programs broaden the company's multiple sclerosis pipeline across different …
The option agreement is designed to complement Tempest Therapeutics' (Nasdaq: TPST) own CD7-targeted lipid nanoparticle in vivo CAR-T platform, which remains in earlier-stage development. By adding a lentiviral vector approach through Senlang, the company gains a second, potentially more durable route to generating CAR-T …
The combined company will be guided by Santersus Chief Executive Officer James Ladtkow and will carry forward a four-program clinical portfolio centered on neutrophil extracellular traps, or NETs. The pipeline is headlined by two candidates that hold FDA Breakthrough Device designation in pivotal-phase development …
The clinical program is structured in two stages. An initial single-arm Phase 2a cohort will assess safety, followed by a randomized Phase 2b stage evaluating therapeutic efficacy. If NV-387 advances through this pathway, NanoViricides (NYSE: NNVC) said it would represent the only oral therapeutic …
Extended monitoring of the TRUST-I study population revealed no novel safety concerns and required no modifications to the existing safety labeling for IBTROZI, according to Nuvation Bio (NYSE: NUVB).
The Australian program builds on earlier progress, including the enrollment of the trial's first patient and a Type B meeting request submitted to the FDA to advance the U.S. regulatory pathway for ONP-002. Oragenics (NYSE American: OGEN) has said it plans to submit an …
The company is targeting clinical trial startup in the fourth quarter of 2026, alongside a pre-BLA Type B discussion with the FDA scheduled for late 2026. OS Therapies (NYSE: OSTX) said the program is supported by leadership from the UK's MHRA within Project Orbis, …
The upcoming presentation follows earlier Phase 1/2 topline results in which ABCL635 met its primary efficacy endpoints, achieving statistically significant reductions in both the frequency and severity of vasomotor symptoms at week four compared with placebo, after just a single dose. AbCellera Biologics (Nasdaq: …